Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Cyxone - Introduction to the share, 29.04.2022

By HC Andersen Capital
Cyxone
Cyxone, a swedish based biotech company active within the area of autoimmune diseases will participate at a digital event hosted by HC Andersen Capital on Friday April 29th where the CEO of Cyxone Tara Heitner will present to give an introduction of the company. Cyxone develops therapies for the two autoimmune diseases rheumatoid arthritis (RA) and multiple sclerosis, where its primary product candidate, Rabexiomed, for RA is in phase 2 and T20K for multiple sclerosis is in Phase 1.
At the event you will get the opportunity to hear more about Cyxone and its product pipeline. Topics for questions and discussion could be the upcoming phase 2b study for RA, the market opportunity for its product candidates and potential for multi-indication of Rabexiomed, its partner and licensing strategy as well as the financial position of the company following the recent rights issue where Cyxone raised more than SEK 60 million.
*HC Andersen Capital receives payment from Cyxone for a DigitalIR/Corporate Visibility agreement.

Recent videos

Orion as an Investment | Life Science Night Dec. 9, 2025
13.12.2025, 12.50 Orion
AKTIER MED FRIIS - UGE 50 2025
12.12.2025, 12.00
HCA Morgenbørs 12/12 - Positive futures og fokus på FLSmidth og fedme aktier
12.12.2025, 09.27 Novo Nordisk
A sit-down with CEO Remco Westermann
12.12.2025, 09.09 Verve Group
Aiforia as an Investment | Life Science Night Dec 9, 2025
11.12.2025, 11.00 Aiforia Technologies
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.